Cargando…
Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells
Although osteosarcoma is the most common primary malignant bone tumor, chemotherapeutic drugs and treatment have failed to increase the five-year survival rate over the last three decades. We previously demonstrated that type 5 metabotropic glutamate receptor, mGluR5, is required to proliferate meta...
Autores principales: | Kang, Min A, Rao, Pooja P., Matsui, Hiroshi, Mahajan, Shahana S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320330/ https://www.ncbi.nlm.nih.gov/pubmed/35887290 http://dx.doi.org/10.3390/ijms23147944 |
Ejemplares similares
-
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice
por: Raghubir, Marian, et al.
Publicado: (2020) -
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole
por: Liao, Sally, et al.
Publicado: (2017) -
Engineering a Novel
Self-Assembled Multi-siRNA Nanocaged
Architecture with Controlled Enzyme-Mediated siRNA Release
por: Moreno, Pedro M. D., et al.
Publicado: (2022) -
Therapeutic potential of mGluR5 targeting in Alzheimer's disease
por: Kumar, Anil, et al.
Publicado: (2015) -
Group I mGluRs in Therapy and Diagnosis of Parkinson’s Disease: Focus on mGluR5 Subtype
por: Azam, Shofiul, et al.
Publicado: (2022)